jRCT2031220334Active, not recruitingNot Applicable
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgaris
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Maruho Co.,Ltd.
- Enrollment
- 40
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Single Arm Study
- Intervention Model
- Single Assignment
- Primary Purpose
- Treatment Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 9age old over to 49age old under (—)
- Sex
- All
Inclusion Criteria
- •Patients with Acne vulgaris 9 to 49 years old
Exclusion Criteria
- •(1)Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •(2)Patients with a history of hypersensitivity to investigational drug ingredients
- •(3)Pregnant or lactating women
Outcomes
Primary Outcomes
-
Percentage change in total lesion count
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Phase 3
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisAcne vulgarisJPRN-jRCT2031220334Tomoyuki Nishiura40
Recruiting
Phase 3
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisJPRN-jRCT2031220333Tomoyuki Nishiura240
Active, not recruiting
Phase 1
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerEUCTR2008-004672-50-ATovartis Pharma Services AG900
Active, not recruiting
Phase 1
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Advanced Ovarian Cancer (FIGO Stage II, Stage III, and Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer).MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-004672-50-DKGlaxoSmithKline Research & Development Ltd900
Active, not recruiting
Phase 1
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerAdvanced Ovarian Cancer (FIGO Stage II, Stage III, and Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer)MedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-004672-50-FRGlaxoSmithKline Research & Development Ltd900